HIV/AIDS Program Contacts

What We Do:

NIDA’s HIV/AIDS research grants are assigned to the Divisions within NIDA based on referral guidelines. Within each Division, there are staff with HIV/AIDS programmatic interests. Brief descriptions of their program areas and e-mail addresses are listed below. Please feel free to contact the appropriate program staff to discuss potential applications.


Division of Therapeutics and Medical Consequences of Drug Abuse

  • Guifang Lao, Ph.D. – neurobehavioral processes underlying HIV risk as treatment targets; including impulsivity and risky decision-making; behavioral and integrative treatments for HIV; integration of risk reduction strategies into treatment of drug use disorders; treatments that promote adherence to HIV medications.
  • Raul Mandler, M.D., FAAN, FANA – medical/clinical consequences of drug abuse and co-occurring infections including HIV, hepatitis (HCV), STDs, TB, and others; interactions between drugs of misuse and medications used in the treatment of drug addiction.

Division of Neuroscience and Behavior

  • Kathleen Borgmann, Ph.D. - neuropathogenic mechanisms of HIV and drug use in glia and other neural cells; HIV CNS reservoir seeding, maintenance, latency and eradication; the neuro-immune dialog; therapeutic gene regulation, delivery and nano formulations; extracellular vesicles; health and gender disparities in the biology of HIV/AIDS and substance use disorders.
  • Yu (Woody) Lin, Ph.D., M.D. – cognitive, neuropsychological and neurobiological sequelae of HIV/AIDS; neuroinflammation; and co-morbidity; cognitive, neuropsychological and neurobiological sequelae of HIV/AIDS and co-morbidity; biomarker development; computational science approach.
  • Holly Moore, Ph.D. – cognitive, affective, and behavioral processes; behavioral models; complex morbidity involving HIV/AIDS; substance use disorders and other psychiatric disorders.
  • Sunila Nair, Ph.D. – mechanisms underlying neurobiological sequelae of HIV/AIDS; Women’s health and sex differences; Circuit neuroscience; HIV/AIDS and substance use disorder comorbidity.
  • Jonathan Pollock, Ph.D. – genetics of HIV host response.
  • John Satterlee, Ph.D. - genomic, epigenomic, or single cell approaches to investigate interactions between addictive substances and HIV progression, latency, or pathogenesis.
  • Shang-Yi (Anne) Tsai, Ph.D. – HIV-associated synaptic plasticity; neuroinflammation; neuroimmunology of CNS HIV reservoirs; neuron-glia mechanisms and interactions.
  • Kiran Vemuri, Ph.D. – chemical biology approaches to understanding HIV and substance use, receptor pharmacology, enzymology, organic synthesis, analytical chemistry, chemical tools/probe development, therapeutics discovery
  • Da-Yu Wu, Ph.D.

Division of Epidemiology, Services, and Prevention Research

  • Sheba Dunston, Ph.D. - risk and protective factors of HIV and drug use, epidemiology, social determinants of health, understanding the impact of social networks, system and structural level factors, social/ behavioral influences and discrimination on HIV infection and the HIV care continuum, substance use patterns that lead to infection, burden of infection and drug use in underserved, racial minority, and sexual minority communities, high risk populations, as well as women and pregnant people, intersectionality, health disparities and health equity.
  • Minnjuan Flournoy Floyd, Ph.D. - organizational, systemic, and structural factors affecting/influencing delivery of HIV services cascade; social/behavioral influences of service engagement/utilization; international research/low-and middle-income countries; mixed-methods research design.
  • Peter Hartsock, Ph.D. – mathematical modeling of HIV and other infectious diseases; molecular epidemiology; international studies.
  • Richard Jenkins Ph.D. - behavioral and social aspects of preventive biomedical trials; community, structural, and policy-level prevention interventions; international HIV prevention; innovative research methods and multi-method research designs; preventive intervention with men who have sex with men; prevention interventions with co-morbid populations.
  • Angela Lee-Winn, Ph.D. – equitable HIV prevention and care research with underserved populations, particularly women & girls; dissemination and implementation (D&I) research; international research; HIV training grants.

Center for Clinical Trials Network

  • Landhing Moran, Ph.D. – research at the intersection of HIV risk and substance use that includes treatment research in people living with HIV/AIDS who use substances (e.g. innovative HIV treatment, HIV and SUD treatment cascades); HIV testing and prevention among higher risk persons using drugs (e.g. new testing technologies, linkage to PrEP, long-acting PrEP); implementation research of linkage-to-care and integration-of-care models.